pemetrexed + BMS-275183

This is a **combination of pemetrexed and BMS-275183**. **Pemetrexed** is a small molecule antifolate chemotherapy agent that inhibits several folate-dependent enzymes involved in de novo biosynthesis of thymidine and purine nucleotides, notably thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, thereby inhibiting DNA and RNA synthesis and leading to cell death in rapidly dividing tumor cells[1][5]. It is approved primarily for malignant pleural mesothelioma and non-squamous non-small cell lung cancer. **BMS-275183** is a novel orally bioavailable taxane that acts as a C-4 methyl carbonate analogue of paclitaxel; its mechanism involves stabilization of microtubules and inhibition of their depolymerization, leading to mitotic arrest and apoptosis of cancer cells[2][4][6]. Unlike paclitaxel, BMS-275183 can be administered orally and avoids the need for solvents associated with hypersensitivity reactions. There is evidence for the utility of each drug separately in non-small cell lung cancer, and preclinical/clinical interest exists for taxane/antifolate combinations, though the specific combination of pemetrexed + BMS-275183 appears experimental.

Other names

pemetrexedBMS-275183BMS275183BMS 275183